PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

About this update from Sera Prognostics, Inc.

-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions. Because NICU care is among the most expensive types of hospital care, reducing admissions has the potential to generate meaningful healthcare savings while improving newborn health outcomes. Four in ten U.S. births are to first-time mothers. Traditional risk assessment tools rely heavily on prior pregnancy history, which is not available in this population. The PreTRM Test enables early risk identification, creating an opportunity for early intervention and improved outcomes. The findings, published in The Journal of Maternal-Fetal & Neonatal Medicine, highlight the clinical value of early risk stratification using the PreTRM® Test combined with accessible interventions in women in their first pregnancy, a large population in which risk is otherwise difficult to predict. Key Findings from PRIME Primigravid Nulliparous Subgroup (n=1,783): In this subgroup of 1,783 nulliparous participants, PreTRM Test-guided care significantly reduced NICU admissions and improved neonatal outcomes compared to routine care. Interventions —including progesterone, low-dose aspirin, and care management— were well tolerated. The screening and treatment approach substantially outperformed traditional methods, supporting its potential as a more effective standard of care in this population without prior birth history. These findings further reinforce the clinical utility of the PreTRM platform in enabling earlier intervention and improving neonatal outcomes. "This study demonstrates the power of tailoring pregnancy care for first-time pregnancies," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "These results show that the PreTRM Test-guided care pathway can improve outcomes in this large subgroup within a pregnant popu...

View stock analysis, news, and events for Sera Prognostics, Inc.